Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready
Prosyla Group PC reports 6 pending office actions in Biotechnology & Pharmaceuticals and 353 career applications. The active unresolved workload is limited relative to the application record shown.
Its resolved allowance rate is 84.47%, with an average of 4.13 office actions per allowance. The figures provide separate views of reported outcomes and prosecution activity, helping practitioners consider whether the profile’s allowance history was achieved through a comparatively active examination process.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (43%) |
| §103 only | 1 (14%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| BROWN, MINDY G | 1 | 57.8% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 13d |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | ABDALHAMEED, MANAHIL MIRGHANI ALI | 25d overdue |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | SALMON, KATHERINE D | 9d |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | BROWN, MINDY G | 13d |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | RICCI, CRAIG D | — |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | BALLARD, KIMBERLY | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Mycomagic Biotechnology Co., Ltd. | 2 |
| EG BIOMED CO., LTD. | 1 |
| Future Pharmtech Inc. | 1 |
| National Health Research Institutes | 1 |
| Yoda Therapeutics | 1 |
| Academia Sinica | 1 |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1627 | 1 |
| 1611 | 1 |
| 1675 | 1 |
| 1600 | 1 |
| 1622 | 1 |
| 1681 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Eg Biomed Co., Ltd. | SALMON, KATHERINE D | 1682 | §101§103 | Non-Final OA | 9d | Pending | Dec 11, 2024 |
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | Future Pharmtech Inc. | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | Mycomagic Biotechnology Co., Ltd. | RICCI, CRAIG D | 1611 | §103 | Final Rejection | — | Pending | Aug 01, 2024 |
| 17996742 | METHODS FOR PREDICTION, DETECTION AND MONITORING OF SUBSTANCEUSE DISORDERS AND/OR AN INFECTION | National Health Research Institutes | BALLARD, KIMBERLY | 1675 | §101§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17821291 | IMMUNOMODULATORY PROTEIN FOR PREVENTION OF CORONAVIRUS INFECTION | Mycomagic Biotechnology Co., Ltd. | SPAINE, ROBERT FRANKLIN | 1600 | §112Other | Non-Final OA | — | Pending | Aug 22, 2022 |
| 17808476 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | Yoda Therapeutics Inc. | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §102 | Non-Final OA | 25d overdue | Pending | Jun 23, 2022 |
| 17806932 | METHOD AND BIOMARKER FOR DETECTION OR DIAGNOSIS OF MYOCARDIAL INFARCTION | Academia Sinica | BROWN, MINDY G | 1681 | §101§112Other | Non-Final OA | 13d | Pending | Jun 14, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.5% of resolved applications prosecuted by Prosyla Group Pc were allowed, across 353 applications in USPTO records.
4.13 office actions per allowed application on average.
7 pending office actions as of October 2026, for 6 clients, before 7 examiners in 7 art units.
